Evidence map›Paper›PMID 34203485›Full record

ArticleCancers2021

The Risk Factors for Radiation Pneumonitis After Single-Fraction Carbon-Ion Radiotherapy for Lung Cancer or Metastasis.

Takashi Ono, Naoyoshi Yamamoto, Akihiro Nomoto, Mio Nakajima, Yuma Iwai, Yuka Isozaki, Goro Kasuya, Hitoshi Ishikawa, Kenji Nemoto, Hiroshi Tsuji

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Takashi OnoDepartment of Radiation Oncology, QST Hospital, Chiba 263-8555, Japan.ORCID 0000-0002-9711-1158
Naoyoshi YamamotoDepartment of Radiation Oncology, QST Hospital, Chiba 263-8555, Japan.
Akihiro NomotoDepartment of Radiation Oncology, QST Hospital, Chiba 263-8555, Japan.
Mio NakajimaDepartment of Radiation Oncology, QST Hospital, Chiba 263-8555, Japan.
Yuma IwaiDepartment of Radiation Oncology, QST Hospital, Chiba 263-8555, Japan.
Yuka IsozakiDepartment of Radiation Oncology, QST Hospital, Chiba 263-8555, Japan.
Goro KasuyaDepartment of Radiation Oncology, QST Hospital, Chiba 263-8555, Japan.
Hitoshi IshikawaDepartment of Radiation Oncology, QST Hospital, Chiba 263-8555, Japan.
Kenji NemotoDepartment of Radiation Oncology, Yamagata University, Faculty of Medicine, 2-2-2, Iida-Nishi, Yamagata 990-9585, Japan.
Hiroshi TsujiDepartment of Radiation Oncology, QST Hospital, Chiba 263-8555, Japan.
Chiba Hospital · JPYamagata University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are no studies on the risk factors of radiation pneumonitis (RP) after carbon-ion radiotherapy at a dose of 50 Gy (relative biological effectiveness (RBE)) in a single fraction. The objective of this study was to identify factors associated with RP after radiotherapy, including dose-volume parameters. Ninety-eight patients without a history of thoracic radiotherapy who underwent treatment for solitary lung tumors between July 2013 and April 2016 were retrospectively analyzed. Treatment was planned using Xio-N. The median follow-up duration was 53 months, and the median clinical target volume was 32.3 mL. Three patients developed grade 2 RP, and one patient developed grade 3 interstitial pneumonitis. None of the patients developed grade 4 or 5 RP. The dose-volume parameters of the normal lung irradiated at least with 5-30 Gy (RBE), and the mean lung dose was significantly lower in patients with grade 0-1 RP than in those with grade 2-3 RP. Pretreatment with higher SP-D and interstitial pneumonitis were significant factors for the occurrence of symptomatic RP. The present study showed a certain standard for single-fraction carbon-ion radiotherapy that does not increase the risk of RP; however, further validation studies are needed.

Indexed as

dose fractionationheavy ion radiotherapyinterstitiallung diseasespulmonary neoplasmsradiationradiation pneumonitis

Identifiers

PMID34203485
PMCPMC8267739
OpenAlexW3175202786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.